PRR is already breaking the bond to Dendreon because
1. Multiple immunotherapy drugs are now out there
2. Dendreon is prostate specific with many competitors
3. Prima's CVAC is uniquely positioned in the market
4. Prima is likely to extend its therapy to other cancers
break the dendron tie, page-5
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 133736 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |